Open AccessBetter survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts
Author(s) -
Sang Il Choi,
Yuri Cho,
Moran Ki,
Bo Hyun Kim,
In Joon Lee,
Tae Hyun Kim,
Seong Hoon Kim,
Kyung-Hun Lee,
Hyun Beom Kim,
Eun Kyung Hong,
In Soo Kim,
Joong-Won Park
Publication year - 2022
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0265668
Subject(s) - medicine , hepatocellular carcinoma , hepatitis b virus , gastroenterology , cohort , confidence interval , hepatitis b , incidence (geometry) , liver cancer , liver function , virus , immunology , physics , optics
Aims The incidence and mortality of hepatocellular carcinoma (HCC) have decreased over time in South Korea, where hepatitis B virus (HBV) in endemic. This study investigated the changes in the characteristics and clinical outcomes of HCC patients in Korea. Methods Patients initially diagnosed with HCC and treated at the National Cancer Center, Korea between 2000 and 2015 (n = 4,291) were followed up until February 2017. Differences in patient characteristics and outcomes were compared between chronological cohorts: cohort A (2000–2004, n = 1,157) vs . B (2005–2009, n = 1,678) vs . C (2010–2015, n = 1,456). Results The median age of the patient cohort was 57 years (range, 13–98 years), and male predominance was noted (81.6%). HBV infection was the most common etiology (74.8%). The proportion of patients diagnosed with good liver function and small tumors (<2 cm) increased significantly over time: 74.6%, 79.9%, and 87.4% for Child–Pugh class A ( p <0.001) and 8.0%, 8.5%, and 12.0% for modified UICC stage I ( p <0.001) in cohorts A, B, and C, respectively. Median overall survival improved significantly over time: 14.4 months (95% confidence interval [CI], 12.0–16.8 months), 22.9 months (95% CI, 20.3–25.5 months), and 53.6 months (95% CI, 45.7–61.5 months) in cohorts A, B, and C, respectively. HBV-related patients showed significantly improved survival (12.7 vs . 20.4 vs . 64.5 months, p <0.001) associated with the use of antiviral treatments (adjusted hazard ratio, 0.72; 95% CI, 0.64–0.80). Conclusions The survival of patients with HCC, especially HBV-related HCC, has improved significantly over time in Korea.